<div id="readability-page-1"><div><ul><li>NRX Pharmaceuticals Inc is expected to show a rise in quarterly revenue when it reports results on August 12 (estimated) for the period ending June 30 2025</li><li>The Wilmington Delaware-based company is expected to report revenue of $1.5 million, according to the mean estimate from 3 analysts, based on LSEG data.</li><li>​LSEG's mean analyst estimate for NRX Pharmaceuticals Inc is for a loss of 20 cents per share. </li><li>The current average analyst rating on the shares is &#34;buy&#34; and the breakdown of recommendations is 4 &#34;strong buy&#34; or &#34;buy,&#34; no &#34;hold&#34; and no &#34;sell&#34; or &#34;strong sell.&#34; </li><li>The mean earnings estimate of analysts was unchanged in the last three months. ​</li><li>Wall Street's median 12-month price target for NRX Pharmaceuticals Inc is $25.00, about 90.2% above its last closing price of $2.46</li></ul>Previous quarterly performance (using preferred earnings measure in US dollars). ​<div><table><tbody><tr><td>QUARTER ENDING</td><td>STARMINESMARTESTIMATE®</td><td>LSEG IBES ESTIMATE </td><td>ACTUAL</td><td>BEAT, MET, MISSED</td><td>SURPRISE %</td></tr><tr><td>Mar. 31 2025</td><td>-0.30</td><td>-0.30</td><td>-0.21</td><td>Beat</td><td>30</td></tr><tr><td>Dec. 31 2025</td><td>-0.31</td><td>-0.32</td><td>-0.77</td><td>Missed</td><td>-143.2</td></tr><tr><td>Sep. 30 2024</td><td>-0.59</td><td>-0.64</td><td>-0.13</td><td>Beat</td><td>79.7​</td></tr><tr><td>Jun. 30 2024</td><td>-0.68</td><td>-0.69</td><td>-0.67</td><td>Beat</td><td>3.6</td></tr><tr><td>​​Mar. 31 2024</td><td>-0.55</td><td>-0.55</td><td>-0.74</td><td>Missed</td><td>-34.5</td></tr><tr><td>Dec. 31 2023</td><td>-0.63</td><td>-0.70</td><td>-0.50</td><td>Beat</td><td>28.6​</td></tr><tr><td>Sep. 30 2023</td><td>-1.15</td><td>-1.13</td><td>-0.70</td><td>Beat</td><td>38.2</td></tr><tr><td>Jun. 30 2023</td><td>-1.50</td><td>-1.37</td><td>-1.20</td><td>Beat</td><td>12.2</td></tr></tbody></table></div>This summary was machine generated August 8 at 12:43 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</div></div>

NRXP

NRX Pharmaceuticals Inc is expected to report a loss of 20 cents per share and quarterly revenue of $1.5 million for the period ending June 30, 2025. The average analyst rating is "buy," with a median 12-month price target of $25.00, significantly above its last closing price of $2.46. Previous earnings performance shows a mix of beats and misses, with the most recent quarter ending March 31, 2025, beating estimates with a loss of 0.21 cents per share.

NRX Pharmaceuticals Inc expected to post a loss of 20 cents a share - Earnings Preview